search
Back to results

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT2)

Primary Purpose

Acute Ischemic Stroke

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Endovascular Thrombectomy
Medical Management
Sponsored by
University Hospitals Cleveland Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke focused on measuring Ischemic stroke, Large vessel occlusion, Endovascular thrombectomy

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults (18-85 years) with the final diagnosis of an acute ischemic stroke
  2. NIH Stroke Scale Score (NIHSS) ≥ 6
  3. Last known well to groin puncture or medical management between 0 to 24 hours
  4. Pre-stroke modified Rankin Scale score (mRS) of 0-1
  5. Eligible for thrombectomy or medical management
  6. Signed Informed Consent obtained
  7. Subject willing to comply with the protocol follow-up requirements
  8. Anticipated life expectancy of at least 3 months

Specific Neuroimaging Inclusion Criteria:

  1. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA

  2. Large infarct-core lesion on at least one of the following:

    • 2.1. Non-Contrast CT (ASPECTS of 3-5),
    • 2.2. CT perfusion (rCBF<30% ≥50cc),
    • 2.3. MRI-DWI (ADC<620 ≥50cc)

Exclusion Criteria:

  1. Inability to undergo CT angiography and/or CT perfusion imaging (e.g., renal insufficiency, iodine/contrast allergy)
  2. Co-morbid psychiatric or medical illnesses that would confound the neurological assessments
  3. Treatment with thrombolytic agent beyond 4.5 hours from last known well

  4. Treated with thrombolytic agent 3-4.5 hours after last known well AND any of the following:

    • 1) age >80,
    • 2) current anticoagulant use,
    • 3) history of diabetes AND prior stroke,
    • 4) NIHSS >25,
    • 5) ischemic involvement of > 1/3 MCA territory
  5. Current participation in another investigational drug or device study.

Neuroimaging Exclusion Criteria

  1. Patients who have both ASPECTS of 6-10 on non-contrast CT AND core volume <50 cc on perfusion imaging
  2. Patients with very large core on non-contrast CT i.e. ASPECTS ≤ 2
  3. Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, neoplasm, or arteriovenous malformation
  4. A significant mass effect with midline shift
  5. Evidence of internal carotid artery dissection that is flow limiting or aortic dissection
  6. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device
  7. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
  8. Signs of established infarct and large area of cerebral edema on non-contrast CT

Sites / Locations

  • Kaiser Permanente
  • Baptist Health
  • Rush University Medical Center
  • Ascension St. Vincent Hospital
  • University of Iowa Hospitals and Clinics
  • University of Kansas Medical Center
  • Spectrum Health Hospital
  • Westchester Medical Center
  • University Hospitals Cleveland Medical Center
  • Cleveland Clinic Foundation
  • Riverside Methodist Hospital - OhioHealth
  • Abington Jefferson Health
  • The Hospital of the University of Pennsylvania
  • Thomas Jefferson University Hospital
  • Semmes Murphey Clinic - University of Tennessee Health Science Center
  • Dell Seton Medical Center at the University of Texas at Austin
  • Valley Baptist Medical Center
  • The University of Texas Health Science Center at Houston
  • Ascension Wisconsin
  • Liverpool Hospital - South Western Sydney Clinical School
  • The Royal Adelaide Hospital (RAH)
  • Royal Melbourne Hospital
  • University of Alberta
  • University Health Network - Toronto Western Hospital
  • Christchurch Hospital
  • Hospital Universitario Germans Trias i Pujol
  • Hospital Clínic i Provincial de Barcelona
  • Hospital Universitari de Bellvitge
  • Hospital Universitari Vall d'Hebron
  • Hospital Clínico Universitario de Valladolid
  • Universität Basel

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Endovascular Thrombectomy plus Medical Management

Medical Management

Arm Description

Outcomes

Primary Outcome Measures

Change in Modified Rankin Scale (mRS) score
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead

Secondary Outcome Measures

Functional independence, defined as mRS score of 0-2 at 90-day follow-up
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead
Independent ambulation, defined as mRS score of 0-3 at 90-day follow-up
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead
Symptomatic intracranial hemorrhage (sICH) as measured by the SITS-MOST criteria
Neurological worsening defined as a ≥4-point increase on the NIHSS score due to the stroke itself
Mortality within 90-day follow-up
Procedural complications
Surgical site hematoma Surgical site infection Vascular injury (peripheral or intracranial dissection, perforation or others) caused by the endovascular procedure
Successful reperfusion in the EVT group, defined as modified Thrombolysis in Cerebral Ischemia (mTICI) grade of 2b or higher
Discharge location
Early neurological improvement, defined as improvement of ≥8 points on NIHSS at 24 hours of presentation or an NIHSS of 0-1
Quality of life score, as measured using NeuroQOL at 90-day follow-up
The 1-year functional outcome, as measured by the modified Rankin Scale score
Functional independence, defined as mRS score of 0-2 at 1-year follow-up
Independent ambulation, defined as mRS score of 0-3 at 1-year follow-up
Quality of life score, as measured using NeuroQOL at 1 year follow-up

Full Information

First Posted
March 8, 2019
Last Updated
December 8, 2022
Sponsor
University Hospitals Cleveland Medical Center
Collaborators
Stryker Neurovascular, The University of Texas Health Science Center, Houston
search

1. Study Identification

Unique Protocol Identification Number
NCT03876457
Brief Title
SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
Acronym
SELECT2
Official Title
SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 11, 2019 (Actual)
Primary Completion Date
November 20, 2022 (Actual)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospitals Cleveland Medical Center
Collaborators
Stryker Neurovascular, The University of Texas Health Science Center, Houston

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
SELECT 2 evaluates the efficacy and safety of endovascular thrombectomy compared to medical management alone in acute ischemic stroke patients due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on either CT (ASPECTS: 3-5) or advanced perfusion imaging ([rCBF<30%] on CTP or [ADC<620] on MRI: ≥50cc) or both and are treated within 0-24 hours from last known well.
Detailed Description
SELECT 2 is a prospective, phase III randomized, international, multicenter, assessor-blinded controlled trial evaluating the efficacy and safety of thrombectomy in patients with large core on either CT or advanced perfusion imaging treated within 0-24 hours from last known well. Patients with the final diagnosis of an acute ischemic stroke due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on either CT (ASPECTS: 3-5) or advanced perfusion imaging ([rCBF<30%] on CTP or [ADC<620] on MRI: ≥50cc) or both within 0-24 hrs from last known well will be randomized in a 1:1 ratio into thrombectomy plus medical management vs medical management alone. Patient outcomes will be measured at baseline, 24 hours post, discharge, 30 days and 90 days. The primary endpoint is the Modified Rankin Scale (mRS) at 90 (+/- 15) days. The primary outcome is a shift on 90-day mRS. Secondary outcomes are favorable clinical outcomes: mRS score of 0-2, safety outcomes such the incidence of symptomatic intracranial hemorrhage (sICH per SITS-MOST) and Imaging endpoints such as infarct volume on MRI diffusion-weighted imaging (DWI) sequence (or CT if MRI not feasible) 24 to 72 hours after randomization. CT images will be read by iSchemaView automated ASPECTS as well as by a physician. In cases where there is disagreement, the physician reading will override the automated software reading. CT/MR perfusion images with mismatch determination will be read by iSchemaView automated RAPID software. All the images will be adjudicated by a blinded core lab at the University of Texas-Medical School at Houston. A maximum of 560 patients will be randomized across the study sites. Covariate adaptive randomization will be used to balance the distribution of important variables. Interim analyses will be conducted at 200 and 380 patients, at which time the study may stop for efficacy or futility.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke
Keywords
Ischemic stroke, Large vessel occlusion, Endovascular thrombectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
352 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Endovascular Thrombectomy plus Medical Management
Arm Type
Experimental
Arm Title
Medical Management
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Endovascular Thrombectomy
Intervention Description
Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
Intervention Type
Other
Intervention Name(s)
Medical Management
Intervention Description
Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
Primary Outcome Measure Information:
Title
Change in Modified Rankin Scale (mRS) score
Description
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead
Time Frame
baseline, 90 days
Secondary Outcome Measure Information:
Title
Functional independence, defined as mRS score of 0-2 at 90-day follow-up
Description
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead
Time Frame
90 days
Title
Independent ambulation, defined as mRS score of 0-3 at 90-day follow-up
Description
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death. Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms. Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Score 6: Dead
Time Frame
90 days
Title
Symptomatic intracranial hemorrhage (sICH) as measured by the SITS-MOST criteria
Time Frame
24 hours
Title
Neurological worsening defined as a ≥4-point increase on the NIHSS score due to the stroke itself
Time Frame
24 hours
Title
Mortality within 90-day follow-up
Time Frame
90 days
Title
Procedural complications
Description
Surgical site hematoma Surgical site infection Vascular injury (peripheral or intracranial dissection, perforation or others) caused by the endovascular procedure
Time Frame
24 hours
Title
Successful reperfusion in the EVT group, defined as modified Thrombolysis in Cerebral Ischemia (mTICI) grade of 2b or higher
Time Frame
at the end of endovascular thrombectomy procedure
Title
Discharge location
Time Frame
day 5-7 after randomization/at discharge (whichever is later)
Title
Early neurological improvement, defined as improvement of ≥8 points on NIHSS at 24 hours of presentation or an NIHSS of 0-1
Time Frame
24 hours
Title
Quality of life score, as measured using NeuroQOL at 90-day follow-up
Time Frame
90 days
Title
The 1-year functional outcome, as measured by the modified Rankin Scale score
Time Frame
1 year
Title
Functional independence, defined as mRS score of 0-2 at 1-year follow-up
Time Frame
1 year
Title
Independent ambulation, defined as mRS score of 0-3 at 1-year follow-up
Time Frame
1 year
Title
Quality of life score, as measured using NeuroQOL at 1 year follow-up
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Infarct volume on MRI DWI sequence (or CT if MRI not feasible) 24 hours to 7 days after randomization
Time Frame
24 hours to 7 days
Title
Lesion growth between the ischemic core on baseline imaging and the follow-up infarct volume
Time Frame
24 hours to 7 days
Title
Parenchymal Hemorrhage type 2
Time Frame
24 hours
Title
Subarachnoid hemorrhage
Time Frame
24 hours
Title
Hemicraniectomy during index hospitalization
Time Frame
day 5-7 after randomization/at discharge (whichever is later)
Title
Length of hospital stay
Time Frame
day 5-7 after randomization/at discharge (whichever is later)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (18-85 years) with the final diagnosis of an acute ischemic stroke NIH Stroke Scale Score (NIHSS) ≥ 6 Last known well to groin puncture or medical management between 0 to 24 hours Pre-stroke modified Rankin Scale score (mRS) of 0-1 Eligible for thrombectomy or medical management Signed Informed Consent obtained Subject willing to comply with the protocol follow-up requirements Anticipated life expectancy of at least 3 months Specific Neuroimaging Inclusion Criteria: Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA Large infarct-core lesion on at least one of the following: 2.1. Non-Contrast CT (ASPECTS of 3-5), 2.2. CT perfusion (rCBF<30% ≥50cc), 2.3. MRI-DWI (ADC<620 ≥50cc) Exclusion Criteria: Inability to undergo CT angiography and/or CT perfusion imaging (e.g., renal insufficiency, iodine/contrast allergy) Co-morbid psychiatric or medical illnesses that would confound the neurological assessments Treatment with thrombolytic agent beyond 4.5 hours from last known well Treated with thrombolytic agent 3-4.5 hours after last known well AND any of the following: 1) age >80, 2) current anticoagulant use, 3) history of diabetes AND prior stroke, 4) NIHSS >25, 5) ischemic involvement of > 1/3 MCA territory Current participation in another investigational drug or device study. Neuroimaging Exclusion Criteria Patients who have both ASPECTS of 6-10 on non-contrast CT AND core volume <50 cc on perfusion imaging Patients with very large core on non-contrast CT i.e. ASPECTS ≤ 2 Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, neoplasm, or arteriovenous malformation A significant mass effect with midline shift Evidence of internal carotid artery dissection that is flow limiting or aortic dissection Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion). Signs of established infarct and large area of cerebral edema on non-contrast CT
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amrou Sarraj, MD
Organizational Affiliation
Case Western Reserve University - University Hospitals Cleveland Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
(Australia and Oceania) Bruce CV Campbell, MBBS PhD
Organizational Affiliation
Melbourne Health
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
(Europe) Marc Ribo, MD
Organizational Affiliation
Vall d'Hebron University Hospital, Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
Baptist Health
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Ascension St. Vincent Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
University of Iowa Hospitals and Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Spectrum Health Hospital
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Facility Name
Westchester Medical Center
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Facility Name
University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Riverside Methodist Hospital - OhioHealth
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
Abington Jefferson Health
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
The Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Thomas Jefferson University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Semmes Murphey Clinic - University of Tennessee Health Science Center
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38163
Country
United States
Facility Name
Dell Seton Medical Center at the University of Texas at Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78712
Country
United States
Facility Name
Valley Baptist Medical Center
City
Harlingen
State/Province
Texas
ZIP/Postal Code
78550
Country
United States
Facility Name
The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Ascension Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Liverpool Hospital - South Western Sydney Clinical School
City
Liverpool
State/Province
New South Wales
Country
Australia
Facility Name
The Royal Adelaide Hospital (RAH)
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Melbourne
State/Province
Victoria
Country
Australia
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
University Health Network - Toronto Western Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Christchurch Hospital
City
Christchurch
State/Province
Canterbury
Country
New Zealand
Facility Name
Hospital Universitario Germans Trias i Pujol
City
Badalona
Country
Spain
Facility Name
Hospital Clínic i Provincial de Barcelona
City
Barcelona
Country
Spain
Facility Name
Hospital Universitari de Bellvitge
City
Barcelona
Country
Spain
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
Country
Spain
Facility Name
Hospital Clínico Universitario de Valladolid
City
Valladolid
Country
Spain
Facility Name
Universität Basel
City
Basel
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35450966
Citation
Sarraj A, Campbell BCV, Christensen S, Sitton CW, Khanpara S, Riascos RF, Pujara D, Shaker F, Sharma G, Lansberg MG, Albers GW; SELECT Investigators. Accuracy of CT Perfusion-Based Core Estimation of Follow-up Infarction: Effects of Time Since Last Known Well. Neurology. 2022 May 24;98(21):e2084-e2096. doi: 10.1212/WNL.0000000000200269. Epub 2022 Apr 21.
Results Reference
derived
PubMed Identifier
34282987
Citation
Sarraj A, Hassan AE, Abraham M, Ribo M, Blackburn S, Chen M, Hussain MS, Pereira VM, Ortega-Gutierrez S, Sitton C, Lavori PW, Cai C, Rahbar M, Pujara D, Shaker F, Lansberg MG, Campbell B, Grotta JC, Albers GW; SELECT2 Investigators. A randomized controlled trial to optimize patient's selection for endovascular treatment in acute ischemic stroke (SELECT2): Study protocol. Int J Stroke. 2022 Jul;17(6):689-693. doi: 10.1177/17474930211035032. Epub 2021 Dec 15.
Results Reference
derived

Learn more about this trial

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

We'll reach out to this number within 24 hrs